Insulet Corporation reported a 23% year-over-year increase in revenue for the first quarter of 2024, exceeding guidance. The company raised its full-year revenue and operating margin outlook due to strong performance across all product lines and strategic launches.
First quarter revenue increased by 23.3% year-over-year to $441.7 million.
U.S. Omnipod revenue increased by 22.7% and International Omnipod revenue increased by 16.9%.
Gross margin increased to 69.5%, up 230 basis points year-over-year.
The company raised its full-year revenue growth expectation to a range of 14% to 18%.
Insulet raised its full year revenue and operating margin guidance. For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%) and is raising its expected operating margin to approximately 13.5% (previously approximately 13%).
Visualization of income flow from segment revenue to net income